Introduction {#S1}
============

In recent years, invasive fungal infections have been increasing all the time due to the widespread use of immunosuppressants and antibiotics, the increase of patients with AIDS, and the development of organ transplantation ([@B72]). The rate of *Candida albicans* isolation ranks fourth and the mortality approximately ups to 40% among patients with bloodstream infections ([@B78]). *C. albicans* infections have become a challenge in clinic ([@B78]). The clinically used antifungal agents are confined to several major types, such as azoles, which inhibit ergosterol biosynthesis, polyenes that combine with ergosterol in the fungal cell membrane, echinocandins that inhibit β-1,3-glucose biosynthesis, and flucytosine that inhibits DNA synthesis ([@B81]). As there are many limitations in clinical application of these antifungal agents, such as limited available drugs, inevitable toxicities, high price, and the emergence of drug resistance, the development of safe and effective antifungal drugs based on novel antifungal targets is urgently needed ([@B14]; [@B81]).

In case of the further researches of fungal pathogenicity, many new antifungal compounds with novel antifungal mechanisms have been identified. Cationic antimicrobial peptides are proved to kill fungi by changing the structure of cell membrane lipid bilayer ([@B77]). E1210 can inhibit fungi catalytic enzymes of GPI-anchored protein synthesis pathways ([@B26]). The Hsp90 inhibitors, such as Mycograb, show antifungal effects by inhibiting Hsp90 ([@B48]; [@B11]).

Besides, previous studies have shown that nutrient metabolism disorders are closely related to fungal virulence ([@B29]; [@B62]). All microorganisms rely on obtaining sufficient nutrients to produce energy to maintain cellular homeostasis, and glucose is one of the important nutrients, thus researches on glucose metabolism have also been focused ([@B41]).

*C. albicans* can obtain glucose from a variety of pathways, such as being transported into cells by glucose transporters, and being synthesized by polysaccharide hydrolysis pathway, gluconeogenesis, trehalose biosynthesis pathway, and galactose metabolism ([@B7]; [@B79]; [@B18]; [@B6]; [@B66]; [@B41]). *C. albicans* also can metabolize glucose to gain energy through glycolytic pathway and TCA cycle ([@B6]; [@B41]). All of these glucose metabolism pathways in *C. albicans* involve a lot of intermediates that are catalyzed by corresponding enzymes ([@B6]). Especially when *C. albicans* invades human bodies, it must adapt to distinct glucose concentrations in different human niches ([@B72]). When *C. albicans* encounters the glucose-shortage environment, such as macrophages or neutrophils, the genes of fatty acid β-oxidation, glyoxylate cycle, and gluconeogenesis are induced, *C. albicans* is able to synthesize glucose through these pathways ([@B6]; [@B9], [@B8]; [@B60]; [@B59]; [@B67]). Whereas *C. albicans* exists in plasma and tissues after escaping from the macrophages or neutrophils, the genes of glycolytic pathway and TCA cycle are induced, and *C. albicans* could resume these pathways to gain energy ([@B6]; [@B9], [@B8]; [@B60]; [@B59]; [@B67]). There are several fungal specific enzymes among these pathways such as acid trehalase, trehalose-6-phosphate synthase, trehalose-6P phosphatase, enolase, class II fructose bisphosphate aldolases, pyruvate kinase, and glucosamine-6-phosphate synthase which are closely related to *C. albicans* virulence, and researches have demonstrated that inhibitors against these specific enzymes have great application prospects against candidiasis ([@B6]). In the following review, we are primarily focusing on the antifungal activities of some compounds with the potential antifungal targets on fungal specific enzymes in glucose metabolism pathways. *C. albicans* glucose metabolism pathways and potential antifungal targets based on these pathways are illustrated in [Figure 1](#F1){ref-type="fig"}. The compounds which have the antifungal activities by disrupting the enzymes of these pathways are summarized in [Table 1](#T1){ref-type="table"}. We believe this review can pave the way for the emergence of new antifungal drugs in the future.

![The structures of compounds against *Candida albicans* by interrupting with glucose metabolism pathways.](fmicb-11-00296-g001){#F1}
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Antifungal activities of compounds against *Candida albicans* by interrupting with glucose metabolism pathways.

  Antifungal compounds                                                                                            Strains                    Antifungal activities                                                                                                                                                Potential antifungal targets                          References
  --------------------------------------------------------------------------------------------------------------- -------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- ------------
  Magnoflorine (MF)                                                                                               *C. albicans ATCC10231*    When MF used alone: MIC = 50 μg/ml; the MIC value of miconazole decreased from 3.125 to 1.5625 μg/ml when combined with 6.25 μg/ml MF                                Alpha-glucosidase                                     [@B32]
  Trehalose-6-phosphate                                                                                           *C. albicans ATCC 36802*   125 μM can inhibit 50--60% TPS1 activity of *Candida albicans*                                                                                                       Trehalose-6-phosphate synthase in trehalose pathway   [@B43]
  Validamycin A                                                                                                   *C. albicans CEY-1*        MIC~50~ = 500 μg/ml                                                                                                                                                  Trehalase in trehalose pathway                        [@B24]
  Mohangamide A                                                                                                   *C. albicans*              IC~50~ = 4.4 μM                                                                                                                                                      Isocitrate lyase in glyoxylate pathway                [@B5]
  Mohangamide B                                                                                                                              IC~50~ = 20.5 μM                                                                                                                                                                                                           
  Apigenin                                                                                                        *C. albicans ATCC10231*    MIC = 125 μg/ml                                                                                                                                                                                                            [@B10]
  Itaconic acid                                                                                                                              MIC = 250 μg/ml                                                                                                                                                                                                            
  Monoterpenoid perillyl alcohol                                                                                  *C. albicans SC5314*       MIC~80~ = 320 μg/ml                                                                                                                                                                                                        [@B3]
  Caffeic acid                                                                                                    *C. albicans ATCC10231*    MIC = 1000 μg/ml                                                                                                                                                                                                           [@B10]
  Alkaloid compounds A                                                                                            *Paracoccidioides* spp.    IC~50~ = 17 μg/ml                                                                                                                                                    Malate synthase in glyoxylate pathway                 [@B12]
  Alkaloid compounds B                                                                                                                       IC~50~ = 29 μg/ml                                                                                                                                                                                                          
  Alkaloid compounds C                                                                                                                       IC~50~ = 21 μg/ml                                                                                                                                                                                                          
  Alkaloid compounds D                                                                                                                       IC~50~ = 17 μg/ml                                                                                                                                                                                                          
  *N*-(4-hydroxybutyl)-glycolohydroxamic acid bis-phosphate *N*-(4-hydroxybutyl)-phospho-glycolohydroxamic acid   *C. albicans*              IC~50~ = 0.003 μg/ml                                                                                                                                                 Class II fructose bisphosphate aldolases              [@B15]
                                                                                                                                             IC~50~ = 0.3 μg/ml                                                                                                                                                                                                         
  *N*-(4-hydroxybutyl)-phospho-glycolohydroxamic acid's hexanoyl ester                                                                       IC~50~ = 0.28 μg/ml                                                                                                                                                                                                        
  *N*-(4-hydroxybutyl)-phospho-glycolohydroxamic acid's lauroyl ester                                                                        IC~50~ = 0.8 μg/ml                                                                                                                                                                                                         
  Phenylhydrazone derivative A                                                                                                               When the compound A was used alone: IC~50~ = 2.7 μg/ml; the IC value of the compound was decreased from 2.7 to 0.0625 μg/ml when combined with 8 μg/ml fluconazole                                                         [@B25]
  *N*^3^-(4-methoxyfumaroyl)-(S)-2,3-diaminopropanoic acid (FMDP) derivative 1                                    *C. albicans ATCC 10231*   MIC = 4 μg/ml                                                                                                                                                        Glucosamine-6-phosphate synthase                      [@B55]
  FMDP derivative 2                                                                                                                          MIC = 32 μg/ml                                                                                                                                                                                                             
  FMDP derivative 3                                                                                                                          MIC = 0.25 μg/ml                                                                                                                                                                                                           [@B54]
  FMDP derivative 4                                                                                                                          MIC = 0.5 μg/ml                                                                                                                                                                                                            
  FMDP derivative 5                                                                                                                          MIC = 0.5 μg/ml                                                                                                                                                                                                            

MIC, minimum inhibitory concentration; IC

50

, half maximal inhibitory concentration.

Potential Antifungal Targets in Glucose Metabolism Pathways {#S2}
===========================================================

In the following, we described the various potential antifungal targets which are proved to be related to *C. albicans* virulence in these glucose metabolism pathways, and several compounds which have antifungal activities based on alpha-glucosidase, acid trehalase, trehalose-6-phosphate synthase, isocitrate lyase, malate synthase, enolase, class II fructose bisphosphate aldolases, and glucosamine-6-phosphate synthase.

Glucose Transporters and Sensors {#S2.SS1}
--------------------------------

Previous studies demonstrated that 20 glucose transporters (HGTs) had been identified in *C. albicans*, and interfering with some HGTs had obvious effects on hyphal formation, virulence, and drug resistance of *C. albicans* ([@B9]; [@B72]). As shown in [Figure 1](#F1){ref-type="fig"}, HGT1 and HGT4 are the important glucose transporter and glucose sensor, respectively, which are required for sensing glucose, galactose, maltose, and fructose in *C. albicans* ([@B74]; [@B9]). HGT1 is a high-affinity glucose transporter in *C. albicans*, and Varma et al. suggested that the expression of HGT1 was significantly increased when used with some antifungal drugs, illustrating that HGT1 is closely related to drug resistance ([@B74]). Brown et al. pointed that the hgt4Δ mutant could not grow normally on media containing glucose, mannose, or fructose at low concentrations, and the hgt4Δ mutant had a growth defect without proper aeration even at high sugar concentration, demonstrating that HGT4 is essential for *C. albicans* growth ([@B9]). Generally, the disruption of genes of glucose transporter and glucose sensor in *C. albicans* was involved with hyphal formation and virulence, and the hgt4Δ null mutant had obvious hyphal formation defects on spider medium compared with the wild-type strains ([@B9]; [@B72]). Moreover, the hgt4Δ mutant also displayed less virulence compared with the wild-type strains, elucidating that HGT4 does have a great influence on *C. albicans* hyphal formation and virulence ([@B9]; [@B72]). Furthermore, the sequence similarities between HGT1/HGT4 in *C. albicans* and GLUTs in humans are less than 30.4% ([@B19]). Therefore, in theory, HGT1 and HGT4 have the possibilities to become potential antifungal targets, but they still need a lot of exploration to determine the feasibility.

Alpha-Glucosidase {#S2.SS2}
-----------------

Alpha-glucosidase is a carbohydrate-degrading enzyme which can hydrolyze disaccharides such as maltose to glucose for subsequent glycolysis and tricarboxylic acid cycle ([@B7]). Alpha-glucosidase I and II in endoplasmic reticulum encoded by CWH41 gene and ROT2 gene, respectively, are also indispensible for *C. albicans N*-oligosaccharide processing, which is essential for host--fungus interaction ([@B53]). cwh41Δ and rot2Δ null mutants displayed delayed filamentation and shorter germ tubes, reduced contents of mannan in cell wall, and decreased virulence in the murine model infected with cwh41Δ and rot2Δ null mutants, demonstrating that alpha-glucosidases are vital for *C. albicans* growth and virulence ([@B53]). Therefore, we believe that the novel antifungal compounds based on alpha-glucosidases can be found. As shown in [Figure 1](#F1){ref-type="fig"}, [@B32] pointed that 150 μM magnoflorine could completely inhibit the formation of *C. albicans* biofilm and magnoflorine has obvious antifungal activity against *C. albicans* with minimum inhibitory concentration (MIC) 50 μg/ml, and the MIC of miconazole was reduced from 3.13 to 1.56 μg/ml when combined with 6.25 μg/ml magnoflorine. In addition, the combination of miconazole and magnoflorine shows a weak synergistic anti-candida effect ([@B32]). Moreover, the cytotoxicity to human cells of magnoflorine was also tested, and it exhibited no toxicity to human cells even in 600 μM of treatment ([@B32]). Thus, magnoflorine based on alpha-glucosidases has no significant toxicity to human cells, and we hope this enzyme could become a potential antifungal target for *C. albicans* infection.

Fructose-1,6-Bisphosphatase {#S2.SS3}
---------------------------

Fructose-1,6-bisphosphatase (FBPase) is a rate-limiting enzyme encoded by FBP1 gene in gluconeogenesis metabolism which is responsible for converting the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate ([@B31]; [@B39]). *C. albicans* which lack the FBP1 gene exhibited significant defects in growing on non-fermentable carbon sources, such as glycerol, acetate, ethanol, citrate, and oleate ([@B59]). Interfering with genes of enzymes in *C. albicans* glucose metabolism pathways is always associated with hyphae formation and virulence. Although fbp1Δ mutant had no difference in yeast--hyphae transition compared with wild-type strains, the virulence of fbp1Δ mutant strain was significantly attenuated in a mouse model with disseminated system candidiasis compared with wild-type strains, demonstrating that FBP1 gene is unnecessary for morphological transition of *C. albicans* in glucose-limited environment but is indeed essential for virulence ([@B18]; [@B59]). Furthermore, FBPase is a highly conserved enzyme in eukaryotes, but there is only 48% sequence homology between *Saccharomyces cerevisiae* and animals ([@B61]). In summary, it is possible for FBPase to become a potential antifungal target theoretically, but more experimental researches are needed to confirm that.

Phosphoenolpyruvate Carboxykinase {#S2.SS4}
---------------------------------

Phosphoenolpyruvate carboxykinase (PEPCKase) is generally regarded as an enzyme which converts oxaloacetate into phosphoenolpyruvate (PEP) and carbon dioxide in gluconeogenesis ([@B82]). In *C. albicans*, pck1/pck1 null mutant grew well on glucose, but they were unable to grow on non-fermentable carbon sources ([@B6]). [@B6] demonstrated that *C. albicans* pck1/pck1Δ null strain showed a moderate decrease in virulence in murine systemic infections compared with wild-type strains, suggesting that PEPCKase is indeed a contributory factor for the virulence of *C. albicans*. Moreover, *C. albicans* PEPCKase has high homology with other ATP-dependent PEPCKase, but there is no homology to the GTP-dependent PEPCKase of animals ([@B37]). Therefore, although there are no developments on antifungal compounds based on this enzyme, these physiopathological studies have made this enzyme possible as a potential antifungal target theoretically, and more researches are needed to confirm the feasibility in the future.

Acid Trehalase and Heat-Shock Proteins {#S2.SS5}
--------------------------------------

[@B57] suggested that acid trehalase (Atc1p) which is encoded by ATC1 gene is located on the cell wall surface, and it is responsible for cleaving off exogenous trehalose and growing on trehalose as a carbon source. *C. albicans* lost acid trehalase activity and could not grow on exogenous trehalose as sole carbon source when ATC1 gene was disrupted ([@B57]). Moreover, ATC1 gene does have influence on *C. albicans* hyphal formation and virulence. ATC1Δ mutated strain displayed a significant decrease in virulence in mice models and a considerable reduction in yeast-to-hyphae transition compared with wild-type strains ([@B56]). However, *C. albicans* ATC1 gene-deficient mutant was more resistant in response to various stimuli such as oxidative stress and heat shock, so the regulation of ATC1 gene in *C. albicans* is very complicated, the usefulness of Atc1p as an antifungal target remained to do more intensive researches ([@B56]; [@B63]). In the development of new antifungal compounds with this enzyme, Guirao-Abad et al. identified the antifungal activity of the Atc1p competitive inhibitor validamycin A, and the MIC~50~ was 500 g/l ([@B24]). In theory, Atc1p has the possibility to be a potential antifungal target; it still needs more exploration to assure the feasibility.

In addition, heat shock proteins (Hsps) such as Hsp90 and Hsp21 are closely related to the trehalose biosynthesis of *C. albicans*. Several reports suggested that Hsp21 in *C. albicans* plays a vital role in adapting to distinct environmental stresses by modulating the homeostasis of trehalose and the activation of stress-responsive kinase Cek1 ([@B50]). Importantly, the hsp21Δ/Δ mutant failed to grow at elevated temperature and exhibited invasive growth defects, significantly shorter filamentation, and increased susceptibility toward oxidative stress and human neutrophils compared with the wild-type strains ([@B50]). Furthermore, hsp21Δ/Δ mutant was more sensitive to various antifungal drugs ([@B49]; [@B23]). Many studies have demonstrated that Hsp90 established vital roles in thermal stability, hyphal formation, apoptosis, and drug resistance in *C. albicans*, and the synergistic effects against FLC-resistant *C. albicans* have also been proved when specific inhibitors of Hsp90 are combined with fluconazole ([@B65]; [@B38]; [@B23]). Therefore, the study of specific inhibitors targeting Hsp90 and the inhibitors in combination with classical antifungals could be promising strategies against *C. albicans* infections. Hsp21 has the possibility to be a potential antifungal target theoretically, but it still requires a lot of exploration to determine the feasibility.

Trehalose-6-Phosphate Synthase {#S2.SS6}
------------------------------

In *C. albicans*, the trehalose-6-phosphate synthase (Tps1P) encoded by TPS1 gene is required for producing trehalose, and it is responsible for catalyzing the first step in trehalose biosynthesis. Except for playing an important role in trehalose biosynthesis, Tps1p is also responsible for *C. albicans* cell viability ([@B1]). The tps1/tps1 null mutant of *C. albicans* lost their high cell viability during severe oxidative stress conditions induced by high concentrations of hydrogen peroxide ([@B1]). Importantly, the TPS1 gene was required for *C. albicans* hyphal formation and virulence, and disruption of TPS1 gene showed a noticeable hyphal conversion defect at 37°C and an obvious decrease in infectivity compared with the wild type in mice models, which means that TPS1 gene is indeed a contributory factor to *C. albicans* viability and virulence ([@B79]). In different media, tps1/tps1 null mutant exhibited distinct phenotypes due to the difference in the over-glycosylation and hydrophobicity ([@B46]; [@B70]). It has been confirmed that tps1/tps1 null mutant was more vulnerable to macrophage killing when cultured in solid media, but the phenotype was reversed in liquid media ([@B46]; [@B70]). However, resistance of *C. albicans* TPS1 gene mutant to different stimulus conditions is different ([@B80]). *C. albicans* TPS1 mutant was more sensitive to severe oxidative stress conditions, but in saline stress or heat shock stress conditions, the sensitivity of TPS1 mutant and the wild type had no remarkable difference ([@B80]). Therefore, in *C. albicans*, the virulence and the susceptibility to stimulus conditions based on Tps1p regulation is complex; more research on the enzyme is still needed to assure if it is proper to become an antifungal target. Fortunately, Tps1p is absent in mammals, so specific Tps1p inhibitors might have little human side effects ([@B43]).

In [Figure 1](#F1){ref-type="fig"}, a new effective antifungal compound has been identified based on Tps1p; trehalose-6-phosphate (T6P) inhibited 50 and 60% activity of *Candida tropicalis* Tps1p and *C. albicans* Tps1p *in vitro* at 125 μM concentration, respectively ([@B43]). Although T6P has unsuitable drug properties and lacks data on *C. albicans* virulence *in vivo*, it provides an effective design idea and the T6P analogs can be developed for novel antifungals in *C. albican*s treatment ([@B43]). It still needs further developments to suggest the therapeutic potential of Tps1p inhibitors in fungal infections, and we believe Tps1p is an important enzyme for developing new anti-candida drugs.

Trehalose-6P Phosphatase {#S2.SS7}
------------------------

Trehalose-6P phosphatase (Tps2p) plays an important role in trehalose biosynthesis pathway which can convert T6P to trehalose and inorganic phosphate ([@B70]). T6P is toxic to *C. albicans* and the disruption of Tps2p protein will accumulate T6P in cells ([@B70]). Importantly, Tps2p and T6P are all absent in mammals, and Tps2p is a specific enzyme to dephosphorylate T6P, so the development of specific Tps2p inhibitors is meaningful ([@B70]). The gene TPS2 encoding Tps2p plays a vital role in the growth and cell viability of *C. albicans*, but no obvious influence on the hyphae formation ([@B71]). During the heat stress condition, the tps2/tps2 null mutant displayed the inhibition of growth and the loss of cell viability, but no difference in yeast--hyphae transition compared with the wild-type strain ([@B71]). Moreover, TPS2 gene was also related to *C. albicans* virulence; the loss of TPS2 gene strongly decreased the virulence in mouse models with system infections because of the T6P accumulation in *C. albicans* ([@B44]). The sensitivity to macrophage phagocytosis of tps2Δ/tps2Δ strain is also quite different compared with wild-type strains, and the results demonstrated that *C. albicans* strain which lacks the TPS2 gene is more susceptible to macrophage engulfment than wild-type strains ([@B47]). Given that Tps2p is essential for *C. albicans* growth, cell viability, and virulence, further development of specific Tps2p inhibitors can help us to identify the novel antifungals against *C. albicans* infections.

Isocitrate Lyase {#S2.SS8}
----------------

Isocitrate lyase (Icl) catalyzes isocitrate to glyoxylate and succinate in the glyoxylate cycle, then succinate is used for the subsequent glucose synthesis pathway ([@B42]). [@B42] identified that the Icl1 mutant strain was unable to utilize acetate or ethanol. Icl was closely associated with the virulence of *C. albicans*, and the mutant which lacks the ICL1 gene was obviously less virulent compared with the wild type in mouse models ([@B42]; [@B6]). Thus, it is worthy to do more researches on Icl, as shown in [Figure 1](#F1){ref-type="fig"}, and currently the development of antifungal compounds based on this target has been carried out ([@B10]; [@B3]). Several studies have identified that apigenin, itaconic acid, monoterpenoid perillyl alcohol, and caffeic acid were potential Icl1 inhibitors against *C. albicans* with the MIC 125--1000 μg/ml, and although their antifungal activities were limited, they proved that the enzyme has potential therapeutic value for exploring new antifungal drugs ([@B10]; [@B5]; [@B3]). Bae et al. demonstrated that Mohangamide A and Mohangamide B also displayed essential antifungal effects; they could inhibit *C. albicans* Icl activity with the IC~50~ 4.4 and 20.5 μM, respectively ([@B5]). These accumulating evidences suggest that doing researches on Icl is valuable, and we believe that continuing to develop more details about this target will reveal new and effective antifungal drugs.

Malate Synthase {#S2.SS9}
---------------

Malate synthase (Mls) encoded by MLS1 gene is another unique enzyme in the glyoxylate cycle, which converts acetyl-CoA and glyoxylate to malate in the glyoxylate cycle ([@B42]). Like the other specific enzyme Icl in the glyoxylate cycle, MLS not only participates in the glyoxylate cycle but also is indispensable for *C. albicans* virulence ([@B42]; [@B3]). The virulence and persistence in systemic candidiasis murine models infected with MLS1 gene mutant was decreased compared with wild-type strains, demonstrating that MLS1 does have influences on *C. albicans* virulence ([@B42]; [@B3]). In *Paracoccidioides*, Mls also played an important role in adhesion and host--fungus interactions, and four alkaloid compounds could inhibit Mls of *Paracoccidioides* with IC~50~ 17--29 μg/ml, which had obvious effects on fungal infections ([@B12]). *C. albicans* Mls also shares significant homology with a lot of microorganisms as well as plants, but not humans, indicating that antifungal compounds based on Mls could have broad antimicrobial effects and limited side effects on human bodies ([@B42]). Therefore, although the antifungal compounds based on *C. albicans* Mls have not been studied yet, we believe that the accumulated evidence suggests that this enzyme is valuable and meaningful for the development of novel antifungal drugs.

UDP-Galactose-4-Epimerase {#S2.SS10}
-------------------------

UDP-galactose-4-epimerase (GAL10) is a key enzyme in the galactose metabolism which is responsible for converting UDP-galactose to UDP-glucose and then can be used for subsequent glycolysis ([@B66]). Comparing with other enzymes in *C. albicans* glucose metabolism, GAL10 not only is involved with hyphae formation but also has influences on the colony morphology ([@B66]). Singh et al. confirmed that the colony morphology had more wrinkles and the hyphal formation was increased in null GAL10 mutant compared with the wild-type strains ([@B66]). Moreover, GAL10 also plays a positive role in improving the sensitivity of antifungal drugs. GAL10 mutant showed hypersensitivity to antifungal agents and oxidative stress conditions ([@B66]). Thus, these accumulated evidences may prove that GAL10 is possible to be a potential antifungal target theoretically; it needs further exploration to determine the possibility.

HXK2 {#S2.SS11}
----

Glycolysis is important for *C. albicans* to develop infections in plasma and tissues due to the ability of assimilating six-carbon compounds; HXK2 is one of the hexokinases in *C. albicans*, and it is responsible for the important step of glycolysis pathway, hexose phosphorylation ([@B18]; [@B6]; [@B4]; [@B67]; [@B36]). HXK2 contributes to *C. albicans* hexose phosphorylation and invasion abilities including filamentation and virulence ([@B36]). The hxk2Δ/Δ mutant not only exhibited an obvious hyphal formation defect compared with the wild-type strains but also displayed much lower virulence in *Galleria mellonella* models and macrophage models, indicating that HXK2 indeed plays an essential role in *C. albicans* infections ([@B36]). Moreover, HXK2 is closely related to physiological process such as high glycolytic metabolism, cell proliferation, apoptosis, and autophagy in tumor cells, and the expression of HXK2 is significantly increased in cancer cells compared with normal cells, so the inhibition of HXK2 is an effective antitumor strategy ([@B73]; [@B76]; [@B83]). In terms of the structure of hexokinases, the mammalian enzyme lacks a segment which corresponds to approximately 35 residues at the *Saccharomyces cerevisiae* enzyme ([@B75]). Although research on antifungal drugs based on this target has not progressed yet, these accumulated evidences and structure differences may prove that HXK2 has the possibility to be a potential antifungal target theoretically, but it needs further exploration to determine the feasibility.

Glyceraldehyde-3-Phosphate Dehydrogenase {#S2.SS12}
----------------------------------------

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an essential glycolytic enzyme located in cytosol which consisted of four subunits; it is responsible for converting glyceraldehyde-3-phosphate to glycerate-1,3-bisphosphate. Except for its significant role in the process of glycolysis in *C. albicans*, GAPDH has been identified as the cytosolic antigen on the cell wall surface which also is enzymatically active ([@B22]). [@B21] and [@B17] suggested that the cell wall-bound GAPDH expressed both on the surface of clinical isolates and on the fungal cells in infected host tissues. Generally, adhesion is associated with tissue invasive process and virulence in *C. albicans* ([@B21]). Because of the ability that GAPDH in *C. albicans* can bind hosts' fibronectin and laminin, it contributes to the progress of adhesion during candidiasis infections ([@B21]). Moreover, GAPDH was reported to be found in the outermost layers of the cell wall, and the anti-GAPDH IgG antibody plays an important role in defining candidiasis infections ([@B64]). In theory, GAPDH is possible to be regarded as a potential antifungal target, and it needs further experimental researches to identify the feasibility.

Enolase {#S2.SS13}
-------

Enolase, also called 2-phospho-[D]{.smallcaps}-glycerate hydrolyase, is one of the central enzymes of glycolysis pathway, catalyzing the dehydration of 2-phosphoglycerate to create phosphoenolpyruvate ([@B68]; [@B69]). Vertebrates contain three kinds of enolases, while *C. albicans* and *Candida glabrata* cells have only one enolase, Eno1 ([@B69]). Eno1 is an immunodominant enzyme which is reported to exist in the inner layers of the cell wall abundantly in *C. albicans* since it shows humoral and cell-mediated immune response ([@B69]; [@B2]). It has been confirmed that *C. albicans* eno1/eno1 null mutant could not grow on a glucose-containing medium, but it was capable of growing on non-fermentable carbon sources containing media, demonstrating that Eno1 is responsible for implicating in glucose metabolism ([@B33]). Besides, [@B30] suggested that *C. albicans* Eno1 is associated with the progress of adhesion, and Eno1 could bind plasminogen and plasmin of host niches, which improved the process of invasion to human brain microvascular endothelial cells. Also, Eno1 not only has influence on host--fungus interactions but also contributes to the sensitivity of antifungal drugs, hyphae formation, and virulence ([@B33]). The eno1/eno1 mutant exhibited higher susceptibility to classical antifungal agents, a remarkable reduction in hyphal formation, and a noticeable decrease in pathogenicity in mice models compared with the wild-type strains ([@B33]). Furthermore, the homology similarity of Eno1 among opportunistic pathogenic fungus such as *C. albicans*, *Aspergillus fumigatus*, and *Cryptococcus neoformans* is relative high, so the inhibitors against this target will have a broad spectrum of antifungal activities ([@B33]). Several reports identified that *C. albicans* Eno1 is the major cell surface antigen and it existed on the outermost layers of the cell wall ([@B58]). Eno1-IgG antibodies exist in patients with candidemia, so monoclonal antibodies against Eno1 may become one of the promising strategies for *C. albicans* infection ([@B58]).

Fructose-1,6-Bisphosphate Aldolase {#S2.SS14}
----------------------------------

Fructose-1,6-bisphosphate aldolase (Fba1p) is an essential enzyme to keep glucose balance both in glycolysis and gluconeogenesis which catalyzes the reversible cleavage reaction of fructose-1,6-bisphosphate (FBP) into two trioses, dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate (G3P) ([@B60]). Fba1p has two mechanically distinct forms: class I Fbas (FBA-I) and class II Fbas (FBA-II). FBA-I is generally found in higher organisms (mammals and plants) and some prokaryotes which forms a covalent Schiff-base intermediate between the dihydroxyacetone moiety of the keto substrate (FBP or DHAP) and a lysine residue of the active site ([@B45]; [@B15]). FBA-II which is encoded by FBA1 gene exists predominantly in the pathogenic microbes in homodimeric form such as fungus and parasites, and they also require a divalent ion (generally Zn^2+^ or Fe^2+^) to maintain the stability of the intermediate metabolites during the catalytic activity and polarize the keto carbonyl group of substrate of the reaction ([@B15]; [@B25]; [@B16]). In addition, *C. albicans* FBA1 gene and its orthologs in several fungus including *Schizosaccharomyces pombe*, *Neurospora crassa*, and *Aspergillus nidulans* show a strong genome sequence conservation, so the inhibitors directly against *C. albicans* FBA-II may have broad antifungal activities against some other fungus ([@B60]). Like most other enzymes in *C. albicans* glucose metabolism, FBA-II not only participates in glucose metabolism but also connects closely with adhesion and virulence ([@B13]; [@B34]). FBA-II was one of the binding proteins of *C. albicans*; the virulence would be impeded if FBA-II was inhibited, elucidating that FBA-II indeed plays a vital role in *C. albicans* virulence ([@B13]; [@B34]). The relationship between *C. albicans* growth and FBA-II has also been confirmed. Rodaki et al. suggested that FBA-II is closely related to the growth of *C. albicans*, and they identified that if the growth is inhibited remarkably, the FBA-II must be dropped to a very low level ([@B60]). However, the loss of FBA-II prevented the growth of *C. albicans* but did not kill it, and the virulence of FBA-II deletion strain partially existed but not eliminated absolutely according to the mouse model of systemic infection ([@B60]; [@B34]). So FBA-II is needed to do further researches to explore more aspects, and in [Figure 1](#F1){ref-type="fig"}, there are antifungal compounds against this target according to some researches.

Several reports identified that *N*-(4-hydroxybutyl)-glycolohydroxamic acid bis-phosphate is the FBP analog which has the 10^5^ selectivity to inhibit the FBA-II, and the IC~50~ value is 0.003 μg/ml ([@B15]). Also, other synthetic compounds of FBP analogs are *N*-(4-hydroxybutyl)-phospho-glycolohydroxamic acid, its hexanoylester, and its lauroylester, which also show strong inhibitory activity and selectivity toward FBA-II, with IC~50~ 0.3, 0.28, and 0.8 μg/ml, respectively ([@B15]). In addition, it has been found that some designed derivatives upon phenylhydrazone against FBA-II especially in *C. albicans* have been identified, such as the compound 3g (mentioned in this review is compound A); compound A is the most potent inhibitor with an IC~50~ value of 2.7 μg/ml, and the IC~50~ value of compound A was decreased from 2.7 to 0.063 μg/ml when combined with 8 μg/ml fluconazole, which showed an obvious synergistic inhibitory activity against resistant *C. albicans* ([@B25]). The accumulating evidence indicated the importance of exploiting the FBA-II inhibitors for antifungal treatment, and we believe that there will be more new effective antifungal drugs produced based on the structure of this target.

Pyruvate Kinase {#S2.SS15}
---------------

Pyruvate kinase (Pyk) is an important enzyme for converting phosphoenolpyruvate (PEP) to pyruvate and ATP in *C. albicans* glycolysis metabolism. The existing form of Pyk is non-identical among mammals, prokaryotes, and lower eukaryotes; there are four distinguishing isoenzymes in mammals, while most prokaryotes and lower eukaryotes have only one isoenzyme, so the inhibitors against Pyk will have limited side effects on humans ([@B35]). Except for the importance of the glycolysis pathway, Pyk also has a greater impact on *C. albicans* virulence ([@B6]). [@B6] suggested that the virulence of *C. albicans* pyk1/pyk1 null mutant was attenuated *in vivo*, and the degree of virulence reduction was more obvious than ICL1/ICL1 mutant or pck1/pck1 strain. In conclusion, the current research on this target is not thorough enough and antifungal compounds have not been discovered, but the evidence indicates that this target is worthy to doing further researches, and we believe that Pyk is a potential good target for developing new antifungal agents.

Glucosamine-6-Phosphate Synthase {#S2.SS16}
--------------------------------

Glucosamine-6-phosphate (GlcN-6-P) synthase catalyzes the irreversible step in UDP--GlcNAc biosynthetic pathway, which transforms [D]{.smallcaps}-fructose-6-phosphate (Fru-6-P) to [D]{.smallcaps}-glucosamine-6-phosphate ([@B28]; [@B51]). GlcN-6-P synthase also exists in mammals, but the inhibition of the enzyme in fungi and mammals has different physiological consequences, so specific inhibitors against GlcN-6-P synthase have little side effects on humans ([@B28]). Except for playing a vital role in chitin biosynthesis pathway, GlcN-6-P synthase also had close relationships with hyphae formation ([@B20]). Several reports identified that the loss of GlcN-6-P synthase phosphorylation by protein kinase A obviously decreases but not completely eliminates the *C. albicans* germination ([@B20]), so the phosphorylation of GlcN-6-P synthase is important for germination and mycelial growth of *C. albicans*.

As shown in [Figure 1](#F1){ref-type="fig"}, currently the development of antifungal compounds based on GlcN-6-P synthase has been carried out. Derivatives of *N*^3^-(4-methoxyfumaroyl)-(*S*)-2,3-diaminopropanoic acid (FMDP) which have great antifungal activities targeted GlcN-6-P synthase have been synthesized, including compounds 4, 5, 11, 12, and 13 (mentioned in this review is FMDP derivatives 1, 2, 3, 4, and 5), with MIC of 4, 32, 0.25, 0.5, and 0.5 μg/ml, respectively ([@B55], [@B54]). These findings indicated the significance of exploiting GlcN-6-P synthase inhibitors for antifungal treatment, and we believe that there will be more new effective antifungal drugs produced based on this target.

GlcN-6-P Acetyltransferase {#S2.SS17}
--------------------------

GlcN-6-P acetyltransferase is the second enzyme encoded by GNA1 gene in UDP--GlcNAc biosynthetic pathway; it is responsible for converting acetyl-CoA and GlcN-6P into CoA and GlcNAc-6P (*N*-acetylglucosamine-6-phosphate) ([@B27]). Several reports pointed that GNA1 gene was efficient for *C. albicans* growth and virulence. The gna1Δ mutant could grow normally in media containing GlcNAc, but it dramatically enlarged, expanded and could not be separated in media without GlcNAc ([@B52]; [@B51]). Furthermore, the gna1Δ mutant exhibited a reduced virulence in the mouse model of candidiasis compared with wild-type strains, indicating that GNA1 gene is important to *C. albicans* virulence ([@B52]; [@B51]). Also, several studies identified the structural difference of the enzyme between fungi and mammals. There is a fungal selective pocket which only positions in fungi, so specific inhibitors against GlcN-6-P acetyltransferase may have little side effects on humans ([@B40]). Therefore, GlcN-6-P acetyltransferase may have the possibility to be a potential antifungal target theoretically, but it still requires a lot of in-depth researches to determine the feasibility.

Discussion {#S3}
==========

As shown in [Table 1](#T1){ref-type="table"}, *C. albicans* adhesion, hyphal formation, and virulence are closely linked to several enzymes in glucose metabolism pathways, and it has been proved that some compounds exert antifungal activities and/or increase the sensitivity to traditional antifungals by inhibiting these enzymes. In addition, several enzymes among these potential antifungal targets are absent in humans or the inhibition of enzymes in fungi and mammals has different physiological consequences, indicating that the specific inhibitors acting on these targets will have little side effects on humans. We believe that by understanding more details between glucose metabolism and *C. albicans*, it will make a lot of sense for reversing drug resistance and developing new drugs against fungal infections.
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